- 2017 American Transplant Congress - Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.- Pharmacy, Northwestern Memorial Hospital, Chicago, IL Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…
- 2017 American Transplant Congress - Donor Derived Transmission Events in 2015-2016: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).- 1DTAC, Richmond; 2United Network for Organ Sharing, Richmond The OPTN DTAC, a multidisciplinary committee, evaluates potential donor derived transmission events (PDDTE), including mostly infections (I) & malignancies (M), to assess for likelihood of…
- 2017 American Transplant Congress - A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…
- 2017 American Transplant Congress - Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
- 2017 American Transplant Congress - Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…
- 2017 American Transplant Congress - Improving Value by Standardizing the Use of IVIG Amongst Pediatric Solid Organ Transplant (SOT) Patients.Background: Given the high cost of pharmaceuticals (i.e. IVIG), we sought to determine if unnecessary variation in drug use may be an opportunity to improve…
- 2017 American Transplant Congress - Safety of Liver Donation from Living Donors with Sickle Cell Trait.Background:Living donor liver transplant (LDLT) is an important source of organs particularly with the cadaveric organ shortage. It is the main source of liver transplant…
- 2017 American Transplant Congress - Risk of Major Bleeding in Solid Organ Transplant Recipients Taking Calcineurin Inhibitors Concomitantly with Direct Oral Anticoagulants Compared to Warfarin.- Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX Purpose: Direct oral anticoagulants (DOAC) and calcineurin inhibitors (CNI) are both substrates of CYP 3A metabolism; therefore, the purpose of this study is to assess…
- 2016 American Transplant Congress - Assessing Vaccination Status in Transplant Candidates and Recipients: Current Status and Challenges to Successful Implementation.- Northwestern University Feinberg School of Medicine, Chicago, IL. Background: Vaccines are safety and efficacy of vaccines in transplant candidates and recipients. Several studies have demonstrated significant underutilization of vaccines which increases the risk…
- 2016 American Transplant Congress - A Multidisciplinary Approach to Reviewing Patient Care in Abdominal Transplantation.- Mount Sinai Hospital, New York, NY. Purpose: Unbiased review of patient care in solid organ transplantation is difficult but essential for improving patient safety. In October 2013 we created a process…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- Next Page »
